close :

:

Forgotten your password?
 
Pharma Industry News
Printable Version   Email to a friend

Kennedy, Ramstad Announce Historic Passage of Paul Wellstone Mental Health Parity Bill

WASHINGTON, March 5, 2008 – Today, Congressman Patrick J. Kennedy (D-RI) announced that the House of Representatives passed the Paul Wellstone Mental Health and Addiction Equity Act of 2007. This historic legislation, sponsored jointly by Kennedy and Congressman Jim Ramstad (R-MN), would improve the overall health of all Americans by granting greater access to mental health and addiction treatment and prohibiting health insurers from placing discriminatory restrictions on treatment.  The legislation was cosponsored by 274 Members of Congress and passed with a strong bipartisan vote of 268 to148.   

 

“Today is a great day for the millions of Americans whose lives are impacted by mental illness and substance abuse,” said Representative Kennedy.  “It is my hope that the passage of this bill will help to erase the stigma associated with mental illness and substance abuse, a stigma which has prevented far too many Americans from seeking out the treatment they need.”

 

“We’ve waited 12 long years for this historic day,” said Representative Ramstad. “I am grateful that the House has taken this important step to end the discrimination against people who need treatment for mental illness and chemical addiction.”

 

“There is no shame in mental illness.  The great shame would be if Congress had not taken action to ensure that individuals with mental health illnesses and addictions are given the attention, treatment, and resources they need to live a healthy life,” Speaker Nancy Pelosi said.  “Today, we have taken a great step forward, and I salute Congressmen Kennedy and Ramstad for their unflagging leadership on this issue.”

 

Named after the late Senator Paul Wellstone, H.R. 1424 aims to realize the late Senator’s vision to establish equality in terms of mental health and addiction health coverage.

 

H.R. 1424 received wide bipartisan support with 274 cosponsors of the bill.  The bill amends ERISA, the Public Health Services Act, and the Internal Revenue Code to eliminate discriminatory provisions that erect obstacles to accessing care for Americans with mental health and addiction disorders.  The 1996 Mental Health Parity Act required equality only for annual and lifetime limits.  H.R. 1424 requires equality across the terms of the health plan, such as:

 

            - The plan or coverage must ensure that any financial requirements applied to mental health and addiction benefits are no more restrictive or costly than the financial requirements applied to substantially all comparable medical and surgical benefits that the plan covers.  The categories for comparison are inpatient   and outpatient, in-network and out-of-network.

 

            - The plan or coverage must also ensure that the treatment limitations applied to such benefits are no more restrictive than the treatment limitations applied to substantially all comparable medical and surgical benefits that the plan covers. Such treatment limitations include limits on the frequency of treatment, number of visits, days of coverage, or other similar limits on the scope and duration of treatment.  

 

            - The plan or coverage must cover the mental illnesses and addiction disorders   included in the APA’s Diagnostic and Statistical Manual of Mental Disorders (DSM), which is the same standard of the federal employee health plan that Members of Congress use.

 

“I am honored to have worked with my colleague and friend Jim Ramstad to reach this important milestone.  I cannot imagine a better way to honor his Congressional career than by ensuring that this legislation reaches the President’s desk by the end of the year,” added Kennedy.


Contact:

407 Cannon House Office Building
Washington, D.C. 20515
(202) 225-4911
Fax: (202) 225-3290

Latest Pharma Industry News...

Pharma Industry News Archive

2008: Jan | Feb | Mar | Apr | May | Jun | Jul
2007: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
2006: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
2005: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
2004: Jan | Feb | Mar | Apr | May | Jul | Aug | Sep | Oct | Nov | Dec
2003: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
2002: Jan | Apr | May | Jun | Aug | Sep | Oct | Nov | Dec

More News Resources


Most Popular Internet Searches
Latest FDA Drug Alerts
July 24, 2008
Audience: Infectious disease and medical genetics healthcare professionals[Posted 07/24/2008] FDA informed healthcare...
July 17, 2008
Audience: Radiological healthcare professionals, cardiologists, hospital risk managers [Posted 07/17/2008] FDA is updating...
July 16, 2008
Audience: Radiologists, surgeons, hospital risk managers, other healthcare professionals [Posted 07/16/2008] FDA informed...
July 16, 2008
Audience: Pharmacists, hospital risk managers, other healthcare professionals[Posted 07/16/2008] Roxane Laboratories, Inc....
More...
Latest Drug Information Updates

Eovist
Eovist (gadoxetate disodium) is a gadolinium-based contrast agent for intravenous use in T1-weighted magnetic resonance imaging (MRI) of the liver to detect and characterize lesions in adults with known or suspected focal liver disease.

Evolence
Evolence is a collagen-based structural dermal filler for the correction of moderate to deep facial wrinkles and folds, such as nasolabial folds.

Kinrix
Kinrix [Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed and Inactivated Poliovirus Vaccine] is a combination vaccine for protection against diphtheria, tetanus, pertussis and polio diseases in children.

Durezol
Durezol (difluprednate ophthalmic emulsion) is a topical steroid for the treatment of postoperative ocular inflammation and pain.

PrandiMet
PrandiMet (repaglinide and metformin HCl) is a fixed-dose combination of the fast-acting secretagogue replaglinide (also known as Prandin) and insulin sensitizer, metformin, indicated for the treatment of type 2 diabetes.

Pentacel
Pentacel is a combination vaccine indicated for active immunization against diphtheria, tetanus, pertussis, poliomyelitis and invasive disease due to Haemophilus influenzae type b in children 6 weeks through 4 years of age.

Trivaris
Trivaris (triamcinolone acetonide) is a glucocorticoid corticosteroid delivered via intravitreal injection for the treatment of sympathetic ophthalmia, temporal arteritis, uveitis, and ocular inflammatory conditions unresponsive to topical corticosteroids.

Entereg
Entereg (alvimopan) is a peripherally-acting mu opioid receptor antagonist used to help patients regain gastrointestinal (GI) function earlier following bowel resection surgery.

OraVerse
OraVerse is a dental anesthetic reversal agent that accelerates the return to normal sensation and function following dental procedures.

Aplenzin
Aplenzin is a once-daily formulation of bupropion hydrobromide indicated for the treatment of depression in adults.

Cimzia
Cimzia is a PEGylated anti-TNF (tumor necrosis factor) biologic therapy for the treatment of moderately to severely active Crohn’s disease in adults.

Relistor
subcutaneous injection for the treatment of opioid-induced constipation

Treximet
Treximet is the first and only migraine product designed to target multiple mechanisms of migraine by combining a triptan, a class of migraine-specific medicines, and an anti-inflammatory pain reliever in a single tablet.

Patanase
Patanase (olopatadine) is an antihistamine nasal spray for the treatment of symptoms of seasonal allergic rhinitis in adults and adolescents twelve years of age and older.

Lexiscan
Lexiscan (regadenoson) is an A2A adenosine receptor agonist indicated for use as a pharmacologic stress agent in radionuclide myocardial perfusion imaging (MPI), a test that detects and characterizes coronary artery disease, in patients unable to undergo adequate exercise stress.

More...